Life Cycle Investment Partners Ltd Purchases Shares of 155,761 STERIS plc $STE

Life Cycle Investment Partners Ltd purchased a new stake in STERIS plc (NYSE:STE) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 155,761 shares of the medical equipment provider’s stock, valued at approximately $39,489,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Board of the Pension Protection Fund purchased a new stake in shares of STERIS in the 4th quarter valued at about $25,000. Harbor Investment Advisory LLC raised its holdings in shares of STERIS by 115.4% in the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 60 shares in the last quarter. Activest Wealth Management raised its holdings in shares of STERIS by 423.8% in the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 89 shares in the last quarter. Cloud Capital Management LLC purchased a new stake in shares of STERIS in the 3rd quarter valued at about $29,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 104 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on STE. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Piper Sandler reissued an “overweight” rating and set a $270.00 price objective on shares of STERIS in a report on Thursday. KeyCorp decreased their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Finally, Weiss Ratings cut STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, April 16th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $274.25.

Insider Transactions at STERIS

In related news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director directly owned 705 shares in the company, valued at $167,233.05. This trade represents a 81.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.07% of the stock is currently owned by insiders.

STERIS Price Performance

STE opened at $216.69 on Friday. The stock’s 50 day simple moving average is $218.41 and its 200 day simple moving average is $242.13. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. STERIS plc has a 1 year low of $195.14 and a 1 year high of $269.44. The firm has a market cap of $21.25 billion, a price-to-earnings ratio of 27.32 and a beta of 0.95.

STERIS (NYSE:STE) last posted its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter in the previous year, the business earned $2.74 earnings per share. STERIS’s revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, analysts predict that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 8th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.